Home Biosimilar Antibodies Others ADC -HER2 Trastuzumab deruxtecan (DS-8201a, T-DXd)
For research use only. Not for use in humans.

Trastuzumab deruxtecan (DS-8201a, T-DXd)

Synonyms: DS-8201

Trastuzumab deruxtecan (DS-8201a, T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activity. Trastuzumab deruxtecan has a molecular weight of 153KDa.

Trastuzumab deruxtecan (DS-8201a, T-DXd)

CAS No. 1826843-81-5

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 98.27% Protein concentration: 20 mg/mL Endotoxin Level: ＜1 EU/mg
98.27

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Trastuzumab deruxtecan (DS-8201a, T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activity. Trastuzumab deruxtecan has a molecular weight of 153KDa.

Product Details

CAS No. 1826843-81-5
Molecular Weight 153000
DAR 7.8
ADC antiody Trastuzumab
ADC cytotoxin DXd
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07553390 NOT_YET_RECRUITING Drug: TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells|Drug: Trastuzum Breast Cancer M.D. Anderson Cancer Center 2026-10-01 PHASE1
NCT07060807 RECRUITING Drug: Paclitaxel|Drug: Nab-paclitaxel|Drug: Capecitabine|Dru Breast Neoplasms Merck Sharp & Dohme LLC 2025-07-21 PHASE3
NCT07578116 NOT_YET_RECRUITING Drug: Cyclin-Dependent Kinase 4 Inhibitor|Drug: Cyclin-Depen Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma SWOG Cancer Research Network 2027-03-09 PHASE3
NCT06643585 RECRUITING Drug: Trastuzumab-Deruxtecan Breast Cancer Prof. Wolfgang Janni 2025-04-22 PHASE3
NCT07022483 RECRUITING Drug: Trastuzumab Deruxtecan|Drug: Chemotherapy Endometrial Cancer Daiichi Sankyo 2025-09-30 PHASE3
NCT07630103 NOT_YET_RECRUITING Drug: Trastuzumab Rezetecan for Injection (SHR-A1811)|Drug: Advanced Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2026-06 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-19)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.